Objective:To investigate the effects of endostar plus paclitaxel and cisplatin (TP) chemotherapy combined with radiotherapy on non-small cell lung cancer (NSCLC) patients and the effect of high mobility group AT-hook2 (HMGA2) and high mobility group box 1 (HMGB1).Methods:In this study,110 non-small cell lung cancer patients in our hospital from February 2013 to May 2015 based on different treatment options were respectively divided into control group (paclitaxel + cisplatin + radiotherapy) or observation group (Endu + paclitaxel + cisplatin + radiotherapy),and the two groups of short-term efficacy and serum HMGA2,HMGB1 content differences were compared.The two groups of patients with adverse reaction rate,quality of life and long-term efficacy after treatment were compared.Results:In the comparison of the effective rate of treatment,the observation group (52.6％) was superior to the control group (22.6％).Meanwhile,the serum HMGA2 and HMGB1 contents in the observation group were lower than those in the control group at 1 week and 1 month after treatment,and the difference was statistically significant.In addition,there was significant difference between the observation group and the control group in the improvement rate (50.9％ vs 18.9％) and recurrence rate (35.1％ vs 64.2％),but there was no significant difference in incidence of adverse reactions.Conolusion:Radiotherapy combined with endostar plus TP regimen can decrease the expression of HMGA2 and HMGB1 in serum,improve the short-term curative effect and quality of life,and reduce the long-term recurrence rate.%目的:探讨恩度联合紫杉醇、顺铂(TP)化疗同步放疗对非小细胞肺癌患者治疗效果及血清中高迁移率族蛋白AT-hook2 (HMGA2)、高迁移率族蛋白B1(HMGB1)的影响.方法:以2013年2月至2015年5月在我院就诊的110例非小细胞肺癌患者为研究对象,依据治疗方案不同分别纳入对照组(紫杉醇+顺铂+放疗)与观察组(恩度+紫杉醇+顺铂+放疗),比较两组近期疗效以及血清中HMGA2、HMGB1的含量差异,同时对两组患者不良反应发生率、治疗后生活质量及远期疗效进行比较.结果:治疗有效率,观察组(52.6％)优于对照组(22.6％);治疗1周及1个月时,观察组患者血清中HMGA2及HMGB1含量均低于对照组,差异均具有统计学意义;观察组与对照组在好转率(50.9％ vs 18.9％)及复发率(35.1％ vs 64.2％)上差异具有统计学意义,但在不良反应发生率上无明显差异.结论:恩度联合TP方案化疗同步放疗可降低患者血清中HMGA2及HMGB1表达量,提高近期疗效及生活质量,降低远期复发率.
展开▼
